Featured Publications
Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer
Silva S, Pereira A, Marta G, de Barros Lima K, de Freitas T, Matutino A, de Azevedo Souza M, de Azevedo R, de Viveiros P, da Silva Lima J, Filassi J, de Andrade Carvalho H, Piato J, Mano M. Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer. The Breast 2017, 38: 39-44. PMID: 29223797, DOI: 10.1016/j.breast.2017.11.012.Peer-Reviewed Original ResearchConceptsPost-operative radiation therapyDisease-free survivalBetter disease-free survivalNeoadjuvant chemotherapyBreast cancerOverall survivalAdvanced breast cancerClinical stage IIIBetter overall survivalAdvanced BC patientsTherapy delayBC patientsClinical impactEarly initiationRadiation therapyStage IIIPatientsSurgeryOptimal timingWeeksChemotherapyFirm conclusionsCancerSurvivalInitiation
2017
Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Retrospective Analysis
Matutino A, Mak M, Takahashi T, Bitton R, Nakazato D, Fraile N, Guimarães R, Gabrielli F, Vasconcelos K, de A. Carvalho H, de Castro G. Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Retrospective Analysis. Journal Of Global Oncology 2017, 4: jgo.17.00059. PMID: 30241202, PMCID: PMC6181177, DOI: 10.1200/jgo.17.00059.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrain NeoplasmsCranial IrradiationFemaleHumansLung NeoplasmsMaleMiddle AgedRetrospective StudiesSmall Cell Lung CarcinomaConceptsExtensive-stage small-cell lung cancerProphylactic cranial irradiationSmall cell lung cancerProgression-free survivalBrain metastasesOverall survivalCranial irradiationLung cancerBenefit of PCISymptomatic brain metastasesFirst-line settingSecond-line chemotherapyKaplan-Meier methodPlatinum-based chemotherapyCareful patient selectionBrain metastasis controlBaseline brainEligible patientsSystemic chemotherapyChemotherapy exposureProgressive diseasePatient selectionTherapeutic challengeDecreased incidencePatient survival
2016
Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community
Protásio B, Matutino A, Lage L, Santana I, Ramos R, Sabbaga J, Capareli F, Saragiotto D, Riechelmann R, Hoff P. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community. Clinical Colorectal Cancer 2016, 16: 65-72. PMID: 27515842, DOI: 10.1016/j.clcc.2016.07.001.Peer-Reviewed Original ResearchConceptsStage III colorectal cancerColorectal cancerClinical trialsHigh riskResected stage III colorectal cancerLogistic regression multivariate analysisStage III CRC patientsDisease-free survivalPredictors of recurrenceRegression multivariate analysisAge 70 yearsLarge cancer centerAdjuvant chemotherapyAdjuvant oxaliplatinFit patientsNeurotoxicity gradeUrgent surgeryAdjuvant regimenAdverse eventsCohort studyCommunity patientsConsecutive patientsCRC patientsMedian agePrognostic factors